Physiological Uptake of ⁶⁸Ga-FAPI-04 in Female Reproductive System.

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Biology Pub Date : 2025-06-01 Epub Date: 2025-04-25 DOI:10.1007/s11307-025-02011-6

Jingshi Mu, Yue Zhang, Yuxiao Xia, Yushan Zhou, Ruoqiu Gan, Qiying Xiang, Minggang Su, Zhiyun Jia

{"title":"Physiological Uptake of 68Ga-FAPI-04 in Female Reproductive System.","authors":"Jingshi Mu, Yue Zhang, Yuxiao Xia, Yushan Zhou, Ruoqiu Gan, Qiying Xiang, Minggang Su, Zhiyun Jia","doi":"10.1007/s11307-025-02011-6","DOIUrl":null,"url":null,"abstract":"Purpose: Since the avid uptake of 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI-04) observed in female reproductive organs, our objectives were to investigate the physiological uptake characteristics and provide preliminary reference ranges for clinical use.Procedures: We reviewed the findings of female patients who underwent 68Ga-FAPI-04 PET/CT at our institution between April 2022 and June 2023. The standard uptake value (SUV) of reproductive organs and menstrual information were collected. All patients were categorized into reproductive period group, perimenopause group, and postmenopause group. We analysed the uptake levels among the three groups, and their association with age and menstrual cycle.Results: A total of 109 patients were included in this study. Higher ovarian SUVs were detected in reproductive patients (SUVright: 2.75 ± 0.84, IQR: 1.39-5.26; SUVleft: 2.72, IQR: 2.34-3.20; p = 0.315) than in postmenopausal patients (SUVright: 2.27, IQR: 2.01-2.75; SUVleft: 2.38 ± 0.55, IQR: 1.35-3.60; p = 0.767), as well as uterine 68Ga-FAPI-04 accumulations. The SUVs of uterine fundus and corpus were approximately three times higher than that of the cervix. In reproductive period group, higher SUVs were observed in bilateral ovaries around the ovulatory phase to the early luteal phase, and higher uterine SUVs were noted in the menstrual and proliferative phases. The SUVs in all reproductive organs (except the ovaries) showed significant negative correlations with age in all patients (all p < 0.01).Conclusions: 68Ga-FAPI-04 SUVs in reproductive organs are higher in premenopausal patients than in postmenopausal patients. The 68Ga-FAPI-04 accumulation in reproductive organs might be associated with menstrual cycle. Including more patients from different menstrual phases could contribute to investigating the uptake characteristics and their underlying mechanisms.","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"474-484"},"PeriodicalIF":2.5000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-025-02011-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Since the avid uptake of ⁶⁸Ga-labeled fibroblast activation protein inhibitor (⁶⁸Ga-FAPI-04) observed in female reproductive organs, our objectives were to investigate the physiological uptake characteristics and provide preliminary reference ranges for clinical use.

Procedures: We reviewed the findings of female patients who underwent ⁶⁸Ga-FAPI-04 PET/CT at our institution between April 2022 and June 2023. The standard uptake value (SUV) of reproductive organs and menstrual information were collected. All patients were categorized into reproductive period group, perimenopause group, and postmenopause group. We analysed the uptake levels among the three groups, and their association with age and menstrual cycle.

Results: A total of 109 patients were included in this study. Higher ovarian SUVs were detected in reproductive patients (SUV_right: 2.75 ± 0.84, IQR: 1.39-5.26; SUV_left: 2.72, IQR: 2.34-3.20; p = 0.315) than in postmenopausal patients (SUV_right: 2.27, IQR: 2.01-2.75; SUV_left: 2.38 ± 0.55, IQR: 1.35-3.60; p = 0.767), as well as uterine ⁶⁸Ga-FAPI-04 accumulations. The SUVs of uterine fundus and corpus were approximately three times higher than that of the cervix. In reproductive period group, higher SUVs were observed in bilateral ovaries around the ovulatory phase to the early luteal phase, and higher uterine SUVs were noted in the menstrual and proliferative phases. The SUVs in all reproductive organs (except the ovaries) showed significant negative correlations with age in all patients (all p < 0.01).

Conclusions: ⁶⁸Ga-FAPI-04 SUVs in reproductive organs are higher in premenopausal patients than in postmenopausal patients. The ⁶⁸Ga-FAPI-04 accumulation in reproductive organs might be associated with menstrual cycle. Including more patients from different menstrual phases could contribute to investigating the uptake characteristics and their underlying mechanisms.

查看原文本刊更多论文

68Ga-FAPI-04在女性生殖系统中的生理摄取。

目的：由于68ga标记的成纤维细胞活化蛋白抑制剂（68Ga-FAPI-04）在女性生殖器官中大量摄取，我们的目的是研究68Ga-FAPI-04的生理摄取特征，为临床使用提供初步参考范围。程序：我们回顾了2022年4月至2023年6月期间在我院接受68Ga-FAPI-04 PET/CT检查的女性患者的结果。采集生殖器官的标准摄取值（SUV）和月经信息。所有患者分为生殖期组、围绝经期组和绝经后组。我们分析了三组的摄取水平，以及它们与年龄和月经周期的关系。结果：本研究共纳入109例患者。生殖期患者卵巢suv较高(SUVright: 2.75±0.84,IQR: 1.39-5.26；SUVleft: 2.72, IQR: 2.34-3.20；p = 0.315)高于绝经后患者(SUVright: 2.27, IQR: 2.01-2.75；SUVleft: 2.38±0.55,IQR: 1.35-3.60；p = 0.767)，以及子宫68Ga-FAPI-04的积累。子宫底和子宫体的suv约为子宫颈的3倍。生殖期组双侧卵巢在排卵期前后至黄体前期均有较高的suv，而在月经期和生殖期子宫suv均有较高的suv。所有患者生殖器官（除卵巢外）的suv均与年龄呈显著负相关（均p）。结论：绝经前患者生殖器官的68Ga-FAPI-04 suv高于绝经后患者。生殖器官中68Ga-FAPI-04的积累可能与月经周期有关。纳入更多来自不同月经期的患者可能有助于研究摄取特征及其潜在机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Biology 医学-核医学

CiteScore

6.90

自引率

3.20%

发文量

审稿时长

3 months

期刊介绍： Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.